PG545 is a heparin sulfate mimetic that is an anti-cancer drug in clinical trials and was recently shown to have potent activity against SARS-CoV2. In this experiment, Ovarian cancer cell lines were treated with PG545 versus control vehicle, and analyzed for differential gene expression with RNASeq to understand what genes and gene pathways are altered by PG545 treatment of ovarian cancer.
Raw RNASeq reads were quantified using Salmon.
Differential gene expression (PG545-treated versus untreated conditions) was quantified using DESeq2.